Revised COVID 19 SARS-COV2 Treatment Protocol - Final

Download as pdf or txt
Download as pdf or txt
You are on page 1of 6

COVID – 19/SARS-COV2 Treatment Protocol

MILD MODERATE SEVERE


Clinical Criteria

SPO2 > 94 % in Room Air 90 - 94 % in Room Air < 90 % in Room Air


RR < 24 / min 24 – 30 > 30
No Pneumonia Pneumonia ++ Pneumonia +++
CT Scoring < 10 CT Scoring > 10
General Investigations to be advised for any COVID Patient
1. CBC
2. CRP
3. Serum Ferritin
4. LDH level
5. LFT
6. Serum Creatinine
7. Blood Urea
8. Serum electrolytes
9. Serum IL-6 levels
10. Plasma D- Dimer level
11. Blood grouping & Typing

If patient has Hypertension, Diabetes, CAD, Dyslipidaemia, Asthma, COPD & Other Ailments
1. Serum Troponin – I levels
2. Serum NT Pro BNP
3. HBA1C
4. Lipid Profile
5. ECG (If Needed)
6. Serum Procalcitonin
7. HRCT Chest
CT Chest Criteria

Normal or < 25 % 25 % - 75 % 75 % to 100 %


Grade I Grade II / III Grade IV
COVID – 19/SARS-COV2 Treatment Protocol

Laboratory Findings (Expected)

NLR < 3.2 > 3.2 > 5.5

CRP < 10 10 – 100 > 100


Ferritin < 500 > 500 > 800

D-Dimer < 0.5 > 0.5 > 1.0

LDH < 300 300 – 400 > 400

IL6 < 4.8 5 – 50 > 80

LFT Normal Slight Derangement Moderate Derangement


COVID – 19/SARS-COV2 Treatment Protocol

Treatment

Routine T. Paracetamol 500 mg T. Paracetamol 500 mg TDS T. Paracetamol 500 mg TDS


TDS
Anti-tussives SOS Anti-tussives SOS Anti-tussives SOS
T. Vitamin C 500 mg BD T. Vitamin C 500 mg BD T. Vitamin C 500 mg BD
T. Zinc 50 mg BD T. Zinc 50 mg BD T. Zinc 50 mg BD
C. Omeprazole 20 mg C. Omeprazole 20 mg BD Inj. Pantoprazole 40 mg IV OD
BD (or) Pan 40 mg OD (or) Pan 40 mg OD
Fluids Adequate Hydration - Adequate Hydration - NS Conservative Fluids
Oral
Antibiotics T. Azithromycin 500 mg T. Azithromycin 500 mg OD x T. Azithromycin 500 mg OD x 5
OD x 5 Days (or) 5 Days Days
T. Amoxiclav 625 mg BD + Inj. Ceftriaxone 1 gm IV BD +
x 5 Days (or) if secondary bacterial Inj. Piptaz 4.5 mg/ Inj meropenam
T. Doxy 100 mg BD x 5 infection suspected 500mg IV TDS if secondary
Days bacterial infection suspected

Anticoagulation T. Eliquis 2.5 mg BD for 7 Inj. Enoxaparin 40 mg SC OD Inj. Enoxaparin 40 mg SC BD x 7


days (or) T. Clopitab-A x 7 Days (can be started as Days (can be started as
OD for 7 days prophylactic without D prophylactic without D DIMER)
DIMER) (Contraindicated in ESRD, active
(Contraindicated in ESRD, bleeding, emergency surgery,
active bleeding, emergency platelets < 20,000/mm3, BP >
surgery, platelets < 200/120) Inj. Dalteparin 5000 IU
20,000/mm3, BP > 200/120) SC OD × 7 day In ESRD, UH –
Inj. Dalteparin 2500 IU SC 5000U SC BD can be used
OD ×7 days
In ESRD, UH – 5000U SC BD
can be used
Steroids To be given if early T. Medrol 16 mg PO/TID for 5 Inj. Dexamethasone 0.2 – 0.4
pneumonia or days (or) mg /kg ≈ 6 mg to 8 mg IV BD x
progressing to moderate T. Dexa 8 mg PO/OD for 5 10 Days or
T. Medrol 16 mg PO/TID days (or) If unresolving inj. Methyl Prednisolone 1.0 -2.0
for 5 days (or) switch to mg/kg ≈ 80 mg x 10 Days
T. Dexa 8 mg PO/OD for Inj. Dexamethasone 0.1 –
5 days 0.2 mg /kg ≈ 6 mg to 8 mg
IV OD x 5 Days or inj.
Methyl Prednisolone 0.5 -1
mg/kg ≈ 60mg x 5 Days
COVID – 19/SARS-COV2 Treatment Protocol

Oxygen Support Not Required To be initiated if SPO2 <94% Maintain Target SPo2
Maintain Target SPo2 of > 90 %
92 to 96 %
NRM (10 -15 lit / min)
Nasal Prongs (4 lit / min) ↓
↓ HFNC (10 - 60 lit / min)
Face Mask (5-10 lit / min) ↓
↓ CPAP (TV 6ml/kg; PEEP 5-15 cm
NRM (10 -15 lit / min) H20; Target PP 30 cm H20)
↓ ↓
HFNC (10 - 40 lit / min) MV (ARDS Protocol)

CPAP (TV 6ml/kg; PEEP 5-15
cm H20; Target PP 30 cm
H20)
Proning Not Indicated Awake Proning (if > 4 L / Prone Ventilation
min) 16 to 18 hrs / Day
- 30 to 120 mins prone
- 30 to 120 mins left lateral
- 30 to 120 mins right lateral
- 30 to 120 mins upright –
Contraindicated in altered
mental status and
hemodynamic instability,
pregnancy
Cytokine Storm
Not I Not Indicated Inj. Toculizumab 400 mg Inj. Toculizumab 400 mg (max
(max 800 mg) slow IV in 100 800 mg) slow IV in 100 ml NS
ml NS over 1 Hour over 1 Hour
Repeat Dose after 12 hours if Repeat Dose after 12 hours if
needed Contra Indications – needed Contra Indications –
Active Infections, TB, Active Infections, TB, Hepatitis,
Hepatitis, Platelets < Platelets < 1L/mm3, ANC <
1L/mm3, ANC < 2000/mm3
2000/mm3

COMORBIDITY AND COMPLICATIONS

Comorbidity Treat Appropriately Treat Appropriately Treat Appropriately


CAD, HT, DM,
Hypothyroid,
Epilepsy
COVID – 19/SARS-COV2 Treatment Protocol

Complications Treat Appropriately Treat Appropriately Treat Appropriately


Septic Shock
AKI, MODS
Delirium
Electrolytes
ECGabnormalities
Stress Ulcers
Liver Dysfunction

Trial Therapies

Anti Viral T. Favipiravir T. Favipiravir Not Indicated


Day 1 – 200 Mg x 9 Tab Day 1 – 200 Mg x 9 Tab
Twice a day Twice a day
Day 2 to Day 14 – 200 Day 2 to Day 14 – 200 Mg x 4
Mg x 4 Tab Twice a day Tab Twice a day

2 Not Indicated Inj. Remdesivir Inj. Remdesivir


200mg IV OD on Day 1 and 200mg IV OD on Day 1 and
100 mg IV OD x 4 Days 100 mg IV OD x 4 Days
Contraindication – Liver Contraindication – Liver
Dysfunction/ CKD / Dysfunction/ CKD /
Pregnancy / Lactation / Pregnancy / Lactation /
Children Children
DI – avoid HCQ, Dexa use DI – avoid HCQ, Dexa use
Methyl Prednisolone Methyl Prednisolone
MONITORING

BP / HR Daily 6th Hourly 4th Hourly


RR/spO2 6th Hourly 2nd Hourly Continuously
CBC / NLR / RFT / Baseline Every 2 Days Daily
LFT
COVID Profile Baseline Once every 4 days Once every 2 days

D Dimer Repeated 4th day Once every 4 days Once every 2 days
ECG If Needed Once every 2 days Daily
ABG - - Daily
X Ray If Needed If Needed If Needed
COVID – 19/SARS-COV2 Treatment Protocol

DISCHARGE CRITERIA

Afebrile > 3 Days Afebrile > 3 Days without Afebrile > 3 Days without
without antipyretics antipyretics antipyretics
+ + +
No Breathlessnes No Breathlessnes No Breathlessnes
10 Days from Symptom 10 Days from Symptom Clinical Recovery
Onset Onset
Repeat RT-PCR if Swab Repeat RT-PCR if Swab Repeat RT-PCR if Swab Negative
Negative Discharge Negative Discharge Discharge
If patient is
Asymptomatic RT-PCR
may not be needed

POST Self Monitoring for 7 Self Monitoring for 7 Days Self Monitoring for 7 Days + POST
DISCHARGE days + POST COVID CARE +POST COVID CARE REHAB COVID CARE REHAB
ADVICE REHAB

Note:

1. This guideline will be updated as more information and research comes


2. An informed consent is required wherever newer/unlicensed tests and therapies are used

Compiled by
Dr. Mahesh Joshi – CEO
Dr. Sai Kumar – Corporate Lead Physician
Dr. Sushant Gupta – Sr. Physician, Hyderabad
Dr. Vishwas Rao – Sr. Physician, Hyderabad
Dr. Asif – Sr. Physician, Delhi
Dr. Ranjit – Lead Physician, Chennai
Dr. Darwin – Sr. Physician, Bangalore
Dr. Arindam Dubey – Sr. Physician, Kolkata

You might also like